Immunotherapy Trial Shows Promising Results for Bowel Cancer Patients

All participants in a groundbreaking bowel cancer trial have remained cancer-free nearly three years after receiving an experimental immunotherapy treatment, according to researchers from University College London and UCL Hospitals.

The study, which focused on 32 patients with stage 2 or 3 bowel cancer, suggests that a short course of immunotherapy before surgery could produce significantly better outcomes than the current standard of care for certain patients.

Researchers specifically targeted patients with tumors displaying a genetic profile known as MMR-deficient or MSI-high, which occurs in approximately 10-15% of bowel cancer cases. This profile indicates a faulty DNA repair system in the body, which scientists hypothesized could make it easier for immunotherapy drugs to identify and attack cancer cells.

Rather than following the traditional approach of surgery followed by chemotherapy, participants received the immunotherapy drug pembrolizumab for up to nine weeks before their scheduled operations. Early data revealed remarkable results, with 59% of patients showing no signs of cancer remaining by the time they underwent surgery.

The latest follow-up data, presented at the American Association for Cancer Research Annual Meeting in San Diego last month, confirms that 33 months after treatment, none of the participants have experienced a cancer recurrence. This includes patients who still had small traces of cancer remaining after surgery that never grew or spread.

“Seeing that no patients have experienced a cancer recurrence after almost three years of follow-up is extremely encouraging, and strengthens our confidence that pembrolizumab is a safe and highly effective treatment to improve outcomes in patients with high-risk bowel cancers,” said chief investigator Dr. Kai-Keen Shiu, a consultant medical oncologist at UCLH and associate professor at UCL.

These results stand in stark contrast to traditional treatment methods. With the standard approach of surgery followed by chemotherapy, approximately 25% of patients with this specific genetic profile would typically see their cancer return within three years, according to the study.

Beyond the immunotherapy itself, the research team implemented innovative monitoring techniques. They utilized personalized blood tests that detect tiny fragments of tumor DNA in the bloodstream, allowing doctors to determine whether the treatment was working even before surgery took place.

“When tumor DNA disappeared from the blood, patients were much more likely to have no cancer remaining, and this matched the long-term results we’re now seeing,” explained first author Yanrong Jiang, a clinical PhD student at the UCL Cancer Institute.

Despite the promising outcomes, the researchers acknowledge several limitations to their study. The trial was relatively small, involving just 32 participants, and focused exclusively on a specific genetic subset of bowel cancer patients. This means the results may not apply universally to everyone with bowel cancer. Additionally, longer follow-up periods are necessary to ensure the cancer doesn’t return in the future.

The findings represent a significant step forward in personalized cancer care, potentially transforming how certain types of bowel cancer are treated. The ability to predict treatment response through blood tests and immune profiling could allow for more tailored approaches to therapy.

“What is particularly exciting is that we now may be able to predict who will respond to the treatment using personalized blood tests and immune profiling,” Dr. Shiu noted. “These tools could help us tailor our approach, identifying patients who are doing well and may need less therapy before and after surgery.”

The results could eventually lead to changes in treatment protocols for bowel cancer patients with the specific genetic profile, potentially reducing the need for chemotherapy and its associated side effects while improving long-term survival rates.

For the millions of people diagnosed with colorectal cancer globally each year, this research offers new hope for more effective, personalized treatment options that could significantly improve quality of life and survival outcomes.